Dominika Domanowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dominika Domanowska has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Adam Niedziela
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Antoni Liebert
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Hanna Wilska
Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
7 shared publications - Martyna Kaplińska
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Natalia Klimek
Warsaw Medical University, 02-091 Warsaw, Poland
7 shared publications - Adrianna Brzozowska
Faculty of Medicine, Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 6 (3(47))
NEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with current therapies offering only modest symptomatic benefits. In recent years, multiple mechanistic approaches have advanced into clinical testing, reshaping therapeutic strategies. Objective: This review synthesizes evidence from the past five years on emerging treatments for AD, highlighting novel disease-modifying agents, biomarker innovations, and adjunctive strategies. Methods: A structured literature search was conducted across PubMed, Embase, and ClinicalTrials.gov for studies published between January 2020 and July 2025. Peer-reviewed articles, pivotal clinical trials, and regulatory documents were included. Findings were organized into five thematic domains: anti-amyloid therapies, tau-targeted interventions, neuroinflammation and innate immunity, metabolic and repurposed drugs, and emerging technologies for drug delivery and diagnostics. Results: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, demonstrated clinically meaningful slowing of cognitive decline in early AD, leading to regulatory approvals. However, safety concerns, particularly amyloid-related imaging abnormalities, remain critical considerations. Tau-targeting therapies have shown modest biomarker and clinical effects, while immune-modulating agents, such as TREM2 agonists, represent promising novel approaches. GLP-1 receptor agonists, intranasal insulin, and lifestyle-based multidomain interventions target metabolic and systemic contributors to AD, with mixed but encouraging results. Technological advances, including focused ultrasound for blood–brain barrier opening and blood-based biomarkers (e.g., plasma p-tau217, GFAP, NfL), are transforming diagnosis and trial design. Despite progress, challenges remain regarding safety, generalizability, and equitable access. Conclusion: AD therapeutics are entering a transformative phase, shifting from purely symptomatic management toward disease modification. Anti-amyloid therapies provide proof of principle but require optimization of safety and implementation. Parallel efforts targeting tau, neuroinflammation, and systemic pathways, coupled with advances in biomarker-driven precision medicine, suggest that future management will likely rely on combination strategies tailored to individual biological profiles.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 6 (3(47))
Open AccessNEW PERSPECTIVES ON ALZHEIMER’S DISEASE TREATMENT: A STRUCTURED SCIENTIFIC REVIEW (2020–2025)
Background: Alzheimer’s disease (AD) remains the leading cause of dementia worldwide, with current therapies offering only modest symptomatic benefits. In recent years, multiple mechanistic approaches have advanced into clinical testing, reshaping therapeutic strategies. Objective: This review synthesizes evidence from the past five years on emerging treatments for AD, highlighting novel disease-modifying agents, biomarker innovations, and adjunctive strategies. Methods: A structured literature search was conducted across PubMed, Embase, and ClinicalTrials.gov for studies published between January 2020 and July 2025. Peer-reviewed articles, pivotal clinical trials, and regulatory documents were included. Findings were organized into five thematic domains: anti-amyloid therapies, tau-targeted interventions, neuroinflammation and innate immunity, metabolic and repurposed drugs, and emerging technologies for drug delivery and diagnostics. Results: Anti-amyloid monoclonal antibodies, including lecanemab and donanemab, demonstrated clinically meaningful slowing of cognitive decline in early AD, leading to regulatory approvals. However, safety concerns, particularly amyloid-related imaging abnormalities, remain critical considerations. Tau-targeting therapies have shown modest biomarker and clinical effects, while immune-modulating agents, such as TREM2 agonists, represent promising novel approaches. GLP-1 receptor agonists, intranasal insulin, and lifestyle-based multidomain interventions target metabolic and systemic contributors to AD, with mixed but encouraging results. Technological advances, including focused ultrasound for blood–brain barrier opening and blood-based biomarkers (e.g., plasma p-tau217, GFAP, NfL), are transforming diagnosis and trial design. Despite progress, challenges remain regarding safety, generalizability, and equitable access. Conclusion: AD therapeutics are entering a transformative phase, shifting from purely symptomatic management toward disease modification. Anti-amyloid therapies provide proof of principle but require optimization of safety and implementation. Parallel efforts targeting tau, neuroinflammation, and systemic pathways, coupled with advances in biomarker-driven precision medicine, suggest that future management will likely rely on combination strategies tailored to individual biological profiles.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
METFORMIN AND THE GUT MICROBIOTA: CHANGES AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Metformin remains the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM), traditionally understood to act through hepatic glucose suppression and improved insulin sensitivity. However, mounting evidence indicates that metformin significantly influences the gut microbiota, which may underlie some of its metabolic and gastrointestinal effects Aim: This review explores metformin’s mechanisms of action via gut microbial modulation, its clinical effects, and side-effect implications, drawing upon recent primary and review literature. Methods: We performed comprehensive searches in databases including PubMed and Google Scholar,using terms such as metformin, mechanisms of metformin, gut microbiota, side effects of metformin, metformin mechanisms gut, and related combinations. We included studies published up to mid-2025, prioritizing human clinical trials, systematic reviews, and mechanistic animal studies. Results: Compelling evidence shows that metformin alters gut microbial composition—increasing taxa like Akkermansia muciniphila, Escherichia, and SCFA-producers—while reducing others. These shifts are linked to improved barrier integrity, altered bile acid signaling (e.g., FXR inhibition, GLP-1 increase), enhanced SCFA production, modulated metabolite profiles (e.g., BCAA, aromatic amino acids), and altered host glucose flux. Clinically, these microbiome changes likely contribute to metformin’s glucose-lowering, weight-modulating, and anti-inflammatory effects but may also underpin gastrointestinal side effects. Conclusion: The gut microbiota is a significant mediator of both beneficial and adverse effects of metformin. Ongoing and future research—especially RCTs and mechanistic human studies—will be critical for harnessing this interaction therapeutically.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessMETFORMIN AND THE GUT MICROBIOTA: CHANGES AND CLINICAL IMPLICATIONS – A LITERATURE REVIEW
Background: Metformin remains the first-line pharmacotherapy for type 2 diabetes mellitus (T2DM), traditionally understood to act through hepatic glucose suppression and improved insulin sensitivity. However, mounting evidence indicates that metformin significantly influences the gut microbiota, which may underlie some of its metabolic and gastrointestinal effects Aim: This review explores metformin’s mechanisms of action via gut microbial modulation, its clinical effects, and side-effect implications, drawing upon recent primary and review literature. Methods: We performed comprehensive searches in databases including PubMed and Google Scholar,using terms such as metformin, mechanisms of metformin, gut microbiota, side effects of metformin, metformin mechanisms gut, and related combinations. We included studies published up to mid-2025, prioritizing human clinical trials, systematic reviews, and mechanistic animal studies. Results: Compelling evidence shows that metformin alters gut microbial composition—increasing taxa like Akkermansia muciniphila, Escherichia, and SCFA-producers—while reducing others. These shifts are linked to improved barrier integrity, altered bile acid signaling (e.g., FXR inhibition, GLP-1 increase), enhanced SCFA production, modulated metabolite profiles (e.g., BCAA, aromatic amino acids), and altered host glucose flux. Clinically, these microbiome changes likely contribute to metformin’s glucose-lowering, weight-modulating, and anti-inflammatory effects but may also underpin gastrointestinal side effects. Conclusion: The gut microbiota is a significant mediator of both beneficial and adverse effects of metformin. Ongoing and future research—especially RCTs and mechanistic human studies—will be critical for harnessing this interaction therapeutically.
- Open Access
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
MIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
- 30 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (3(47))
Open AccessMIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
- Open Access
- 5 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
LUSPATERCEPT – AN INNOVATIVE APPROACH TO THE TREATMENT OF ANEMIA IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES
Ineffective erythropoiesis (IE) is a hallmark of several hematologic disorders, including β-thalassemia and myelodysplastic syndromes (MDS), leading to chronic anemia and transfusion dependence. IE is often driven by disrupted late-stage erythroid maturation, mediated by overactivation of the Smad2/3 signaling pathway within the transforming growth factor-β (TGF-β) superfamily. This review summarizes current evidence on the mechanism of action and clinical efficacy of luspatercept, a novel activin receptor ligand trap that enhances erythroid maturation by inhibiting Smad2/3 signaling. A literature search was conducted using PubMed through February 2025, focusing on clinical trials and mechanistic studies of luspatercept in β-thalassemia and MDS. In β-thalassemia, luspatercept significantly reduced transfusion burden in phase I–III trials. The pivotal BELIEVE study demonstrated that ≥33% transfusion reduction was achieved in a significantly higher proportion of patients receiving luspatercept compared to placebo. In low-risk MDS (LR-MDS), phase II PACE-MDS and phase III COMMANDS trials showed that luspatercept induced erythroid response (HI-E) and transfusion independence (RBC-TI) in a substantial proportion of patients. COMMANDS further revealed that luspatercept outperformed epoetin alfa in achieving ≥12-week RBC-TI and ≥1.5 g/dL hemoglobin increase, regardless of SF3B1 mutation status or baseline erythropoietin levels. Luspatercept presents a promising treatment strategy for IE in β-thalassemia and LR-MDS. Its ability to promote erythropoiesis, reduce transfusion needs, and maintain a favorable safety profile supports its potential as a new standard of care. Ongoing research will help define its role across broader patient populations.
- 5 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessLUSPATERCEPT – AN INNOVATIVE APPROACH TO THE TREATMENT OF ANEMIA IN BETA-THALASSEMIA AND MYELODYSPLASTIC SYNDROMES
Ineffective erythropoiesis (IE) is a hallmark of several hematologic disorders, including β-thalassemia and myelodysplastic syndromes (MDS), leading to chronic anemia and transfusion dependence. IE is often driven by disrupted late-stage erythroid maturation, mediated by overactivation of the Smad2/3 signaling pathway within the transforming growth factor-β (TGF-β) superfamily. This review summarizes current evidence on the mechanism of action and clinical efficacy of luspatercept, a novel activin receptor ligand trap that enhances erythroid maturation by inhibiting Smad2/3 signaling. A literature search was conducted using PubMed through February 2025, focusing on clinical trials and mechanistic studies of luspatercept in β-thalassemia and MDS. In β-thalassemia, luspatercept significantly reduced transfusion burden in phase I–III trials. The pivotal BELIEVE study demonstrated that ≥33% transfusion reduction was achieved in a significantly higher proportion of patients receiving luspatercept compared to placebo. In low-risk MDS (LR-MDS), phase II PACE-MDS and phase III COMMANDS trials showed that luspatercept induced erythroid response (HI-E) and transfusion independence (RBC-TI) in a substantial proportion of patients. COMMANDS further revealed that luspatercept outperformed epoetin alfa in achieving ≥12-week RBC-TI and ≥1.5 g/dL hemoglobin increase, regardless of SF3B1 mutation status or baseline erythropoietin levels. Luspatercept presents a promising treatment strategy for IE in β-thalassemia and LR-MDS. Its ability to promote erythropoiesis, reduce transfusion needs, and maintain a favorable safety profile supports its potential as a new standard of care. Ongoing research will help define its role across broader patient populations.
- Open Access
- 19 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
POSTOPERATIVE PAIN MANAGEMENT IN DENTISTRY: A NARRATIVE REVIEW OF THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Background. Postoperative pain is a frequent consequence of dental procedures and significantly affects patient comfort and recovery. The severity and duration of pain vary depending on the type of procedure and individual patient factors. Although it usually resolves within a few days, in some cases it may become chronic. Effective pain management is therefore essential. Aim. This review presents contemporary strategies for managing postoperative dental pain, with particular emphasis on the use and efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review was conducted using PubMed and Google Scholar. Relevant peer-reviewed original articles, systematic reviews, and clinical trials published in English were selected. The inclusion criteria focused on studies concerning the use of NSAIDs in various dental disciplines, including conservative dentistry, pediatric dentistry, orthodontics, periodontology, prosthetics, and oral and maxillofacial surgery. Articles not related to dental postoperative pain or NSAID use, case reports, and expert opinions were excluded. Results. NSAIDs such as ibuprofen, ketoprofen, and selective COX-2 inhibitors have proven effective in reducing postoperative dental pain across a broad range of procedures. Their mechanism involves cyclooxygenase inhibition and modulation of inflammatory pathways. In many clinical scenarios, NSAIDs surpass opioids and paracetamol alone in efficacy. Preoperative administration is often beneficial, especially in pediatric and orthodontic cases. Additional non-pharmacological methods, such as cryotherapy and laser therapy, further enhance outcomes. However, gastrointestinal, renal, and cardiovascular risks must be considered. Conclusions. NSAIDs are fundamental in managing postoperative dental pain due to their anti-inflammatory and analgesic properties. The best outcomes are achieved through a personalized, multimodal approach combining NSAIDs with non-pharmacological strategies, ensuring effective pain relief while minimizing adverse effects.
- 19 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessPOSTOPERATIVE PAIN MANAGEMENT IN DENTISTRY: A NARRATIVE REVIEW OF THE USE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
Background. Postoperative pain is a frequent consequence of dental procedures and significantly affects patient comfort and recovery. The severity and duration of pain vary depending on the type of procedure and individual patient factors. Although it usually resolves within a few days, in some cases it may become chronic. Effective pain management is therefore essential. Aim. This review presents contemporary strategies for managing postoperative dental pain, with particular emphasis on the use and efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs). Material and methods. A narrative review was conducted using PubMed and Google Scholar. Relevant peer-reviewed original articles, systematic reviews, and clinical trials published in English were selected. The inclusion criteria focused on studies concerning the use of NSAIDs in various dental disciplines, including conservative dentistry, pediatric dentistry, orthodontics, periodontology, prosthetics, and oral and maxillofacial surgery. Articles not related to dental postoperative pain or NSAID use, case reports, and expert opinions were excluded. Results. NSAIDs such as ibuprofen, ketoprofen, and selective COX-2 inhibitors have proven effective in reducing postoperative dental pain across a broad range of procedures. Their mechanism involves cyclooxygenase inhibition and modulation of inflammatory pathways. In many clinical scenarios, NSAIDs surpass opioids and paracetamol alone in efficacy. Preoperative administration is often beneficial, especially in pediatric and orthodontic cases. Additional non-pharmacological methods, such as cryotherapy and laser therapy, further enhance outcomes. However, gastrointestinal, renal, and cardiovascular risks must be considered. Conclusions. NSAIDs are fundamental in managing postoperative dental pain due to their anti-inflammatory and analgesic properties. The best outcomes are achieved through a personalized, multimodal approach combining NSAIDs with non-pharmacological strategies, ensuring effective pain relief while minimizing adverse effects.
- Open Access
- 18 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
NORADRENALINE OR DOPAMINE IN SEPTIC SHOCK - A LITERATURE REVIEW
Introduction and purpose: Septic shock is a common cause of death that is hard to treat and choosing the most effective medication remains a major clinical challenge. The aim of this study is to provide key information about this clinical condition and to compare the drugs most frequently used in the treatment process: noradrenaline and dopamine. Materials and methods: A literature search was conducted using the medical database PubMed and Google Scholar. Articles were retrieved using the keywords: ,,Noradrenaline” ,,Dopamine” ,,Sepsis” ,,Septic shock” ,,Hipotension” in appropriate configuration. Results: 8 studies were found with relevant topics. For of these studies were excluded due to lack of information in the articles or discrepancies in their topics. Finally, 4 meta-analyses were systematically analyzed in our work. Conclusions: According to the available medical literature, recommendations and guidelines, the use of Noradrenaline in patients with septic shock is usually the most appropriate choice. However, the choice of Dopamine is also available, especially in patients with bradycardia, but its use can be linked with a higher risk of cardiac complications.
- 18 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(47))
Open AccessNORADRENALINE OR DOPAMINE IN SEPTIC SHOCK - A LITERATURE REVIEW
Introduction and purpose: Septic shock is a common cause of death that is hard to treat and choosing the most effective medication remains a major clinical challenge. The aim of this study is to provide key information about this clinical condition and to compare the drugs most frequently used in the treatment process: noradrenaline and dopamine. Materials and methods: A literature search was conducted using the medical database PubMed and Google Scholar. Articles were retrieved using the keywords: ,,Noradrenaline” ,,Dopamine” ,,Sepsis” ,,Septic shock” ,,Hipotension” in appropriate configuration. Results: 8 studies were found with relevant topics. For of these studies were excluded due to lack of information in the articles or discrepancies in their topics. Finally, 4 meta-analyses were systematically analyzed in our work. Conclusions: According to the available medical literature, recommendations and guidelines, the use of Noradrenaline in patients with septic shock is usually the most appropriate choice. However, the choice of Dopamine is also available, especially in patients with bradycardia, but its use can be linked with a higher risk of cardiac complications.
- Open Access
- 6 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
THE IMPACT OF CREATINE SUPPLEMENTATION ON COGNITIVE FUNCTION IN ELDERLY: A SYSTEMATIC REVIEW
Introduction: Age-related cognitive decline is a growing public health concern, affecting daily functioning and quality of life. Recent studies suggest that creatine supplementation may improve cognitive performance by supporting mitochondrial function and reducing oxidative stress. However, findings are mixed. This systematic review examines the effects of creatine supplementation on cognitive functions in older adults. Methods: A systematic review was conducted following PRISMA guidelines. PubMed/Medline and EMBASE databases (2003–2025) were searched using the phrase “the effect of creatine supplementation on cognitive functions in the elderly.” After screening 35 studies, four systematic reviews and meta-analyses met inclusion criteria. These studies assessed cognitive function through neuropsychological tests measuring memory, attention, executive function, and processing speed. Results: Meta-analyses indicated favorable effects of creatine on memory and processing speed in older adults. Xu et al. reported significant improvements in memory (SMD = 0.31, 95% CI: 0.18–0.44) and processing speed (SMD = −0.51, 95% CI: −1.01 to −0.01), with no significant effect on global cognition or executive function. Prokopidis et al. found the most pronounced effects in adults aged 66–76. McMorris et al. highlighted inconsistencies across studies, while Stares et al. found no additional benefit when creatine was combined with resistance training. Conclusions: Creatine supplementation may offer moderate cognitive benefits, particularly for memory and processing speed, in older adults—especially those with low baseline creatine or cardiovascular issues. Effects on global cognition and executive function appear limited. More high-quality, long-term randomized controlled trials are needed. Creatine’s neuroprotective properties may support its use in cognitive health strategies, especially alongside physical activity and proper nutrition.
- 6 August 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- No. 3(47)
Open AccessTHE IMPACT OF CREATINE SUPPLEMENTATION ON COGNITIVE FUNCTION IN ELDERLY: A SYSTEMATIC REVIEW
Introduction: Age-related cognitive decline is a growing public health concern, affecting daily functioning and quality of life. Recent studies suggest that creatine supplementation may improve cognitive performance by supporting mitochondrial function and reducing oxidative stress. However, findings are mixed. This systematic review examines the effects of creatine supplementation on cognitive functions in older adults. Methods: A systematic review was conducted following PRISMA guidelines. PubMed/Medline and EMBASE databases (2003–2025) were searched using the phrase “the effect of creatine supplementation on cognitive functions in the elderly.” After screening 35 studies, four systematic reviews and meta-analyses met inclusion criteria. These studies assessed cognitive function through neuropsychological tests measuring memory, attention, executive function, and processing speed. Results: Meta-analyses indicated favorable effects of creatine on memory and processing speed in older adults. Xu et al. reported significant improvements in memory (SMD = 0.31, 95% CI: 0.18–0.44) and processing speed (SMD = −0.51, 95% CI: −1.01 to −0.01), with no significant effect on global cognition or executive function. Prokopidis et al. found the most pronounced effects in adults aged 66–76. McMorris et al. highlighted inconsistencies across studies, while Stares et al. found no additional benefit when creatine was combined with resistance training. Conclusions: Creatine supplementation may offer moderate cognitive benefits, particularly for memory and processing speed, in older adults—especially those with low baseline creatine or cardiovascular issues. Effects on global cognition and executive function appear limited. More high-quality, long-term randomized controlled trials are needed. Creatine’s neuroprotective properties may support its use in cognitive health strategies, especially alongside physical activity and proper nutrition.